StockNews.com Begins Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

Research analysts at StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note issued to investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Down 25.5 %

Shares of NASDAQ BLPH opened at $0.01 on Friday. The stock has a market capitalization of $146,796.00, a price-to-earnings ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.02. The firm has a 50-day moving average price of $0.02 and a 200 day moving average price of $0.03.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.